Gabather reports positive preliminary fMRI results from the ongoing clinical study of GT-002
Wednesday 1 March 2023 Gabather AB (publ) (''Gabather'') reports positive preliminary fMRI data for the first four subjects in the ongoing clinical study of the drug candidate GT-002. High-quality fMRI results show interesting differences in brain activity between the treatment groups, with particularly interesting results within the “Default Mode Network” (DMN), which monitors the flow of thought in the brain.The study is a double-blind EEG/fMRI study with the aim to explore "target engagement”, which means studying the drug interaction with the GABA\A\-receptor and which parts of the